We use cookies

Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.

You can change your choice at any time.

MMedXYNews
HomeVideos
MedXY AI/MedXY News/Tag: Parkinson's disease
MedXY News
EnglishTag

Parkinson's disease

Ask MedXY AI
type 2 diabetesclinical trialheart failureimmunotherapyobesitycardiovascular riskatrial fibrillationbiomarkerscritical careclinical trialsHypertensionartificial intelligenceCardiologyoncologypublic healthtype 1 diabetesdiabetesMortalityAlzheimer's diseasecardiovascular diseasebreast cancerepidemiology

Latest news

Tag

Reevaluating Levodopa’s Role in Freezing of Gait Among Parkinson’s Disease Patients: Insights from NS-Park and PPMI Cohorts
NeurologyParkinson's diseaseFreezing of Gait

Reevaluating Levodopa’s Role in Freezing of Gait Among Parkinson’s Disease Patients: Insights from NS-Park and PPMI Cohorts

By MedXY|Sep 15, 2026

Analysis of two large cohorts reveals no significant association between levodopa use and freezing of gait in Parkinson’s disease after adjusting for disease severity and duration, emphasizing the primary role of disease progression in this

Smoking, Exhaled Carbon Monoxide, and Parkinson’s Disease Risk: Epidemiological Insights and Mechanistic Perspectives
Clinical Updatesneurodegenerationsmoking
© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story

Smoking, Exhaled Carbon Monoxide, and Parkinson’s Disease Risk: Epidemiological Insights and Mechanistic Perspectives

By MedXY|Sep 12, 2026

This review explores evidence linking smoking and exhaled carbon monoxide levels to reduced Parkinson’s disease risk, emphasizing a potential protective role of carbon monoxide, supported by recent large-scale cohort data and biologic

Common MC1R Variants and Parkinson Disease Progression
NeurologyParkinson's diseaseDisease Progression

Common MC1R Variants and Parkinson Disease Progression

By MedXY|Sep 12, 2026

This study links MC1R loss-of-function variants to faster motor decline and phenoconversion in Parkinson’s disease, suggesting their value for prognosis and clinical trial design in European descent patients.

Tavapadon in Early Parkinson’s Disease: Promising Phase 3 Trial Highlights Safety and Motor Symptom Benefits
NeurologyD1/D5 agonistMotor symptoms

Tavapadon in Early Parkinson’s Disease: Promising Phase 3 Trial Highlights Safety and Motor Symptom Benefits

By MedXY|Aug 9, 2026

The phase 3 TEMPO-2 trial demonstrates that flexible-dose tavapadon, a selective D1/D5 dopamine receptor agonist, significantly improves motor symptoms in early Parkinson’s disease with a manageable safety profile, warranting further

Parkinson’s Disease Genetics Across Diverse Ancestries: An Observational Genetic Study of Causal and Risk Variants with Translational Implications
Clinical UpdatesgeneticsParkinson's disease

Parkinson’s Disease Genetics Across Diverse Ancestries: An Observational Genetic Study of Causal and Risk Variants with Translational Implications

By MedXY|Aug 4, 2026

This review synthesizes evidence from a large-scale multi-ancestry study revealing ancestry-specific distributions of Parkinson’s disease genetic variants, emphasizing the need for diverse population inclusion to optimize diagnosis an

Safety and Efficacy of Staged, Bilateral MRgFUS Pallidothalamic Tractotomy in Parkinson’s Disease Motor Complications: A Contemporary Evidence Review
Clinical Updatesclinical trialmotor complications

Safety and Efficacy of Staged, Bilateral MRgFUS Pallidothalamic Tractotomy in Parkinson’s Disease Motor Complications: A Contemporary Evidence Review

By MedXY|Jul 3, 2026

This review synthesizes evidence on staged, bilateral MRgFUS pallidothalamic tractotomy for Parkinson’s motor complications, highlighting demonstrated unilateral safety and modest bilateral efficacy with increased adverse events, unde

Selective D1/D5 Agonism: TEMPO-3 Trial Positions Tavapadon as a Significant Advancement for Parkinson’s Motor Fluctuations
NeurologyDopamine AgonistMotor Fluctuations

Selective D1/D5 Agonism: TEMPO-3 Trial Positions Tavapadon as a Significant Advancement for Parkinson’s Motor Fluctuations

By MedXY|Mar 22, 2026

The Phase 3 TEMPO-3 trial demonstrates that tavapadon, a selective D1/D5 agonist, significantly increases ‘good-on-time’ and reduces ‘off-time’ in Parkinson’s patients with motor fluctuations, offering a favorable sa

The Smart Thermostat for the Brain: How Adaptive DBS is Redefining Parkinson’s Treatment
Neurologymedical innovationneurology

The Smart Thermostat for the Brain: How Adaptive DBS is Redefining Parkinson’s Treatment

By MedXY|Jan 2, 2026

A groundbreaking clinical trial reveals that adaptive deep brain stimulation (aDBS) provides a safer, more efficient, and personalized way to manage Parkinson’s disease symptoms by responding to real-time brain activity.

The Evolving Genetic Landscape of Parkinson’s Disease: Global Prevalence, Phenotypic Correlations, and the Precision Medicine Imperative
Clinical UpdatesGBA1遺伝学的検査

The Evolving Genetic Landscape of Parkinson’s Disease: Global Prevalence, Phenotypic Correlations, and the Precision Medicine Imperative

By MedXY|Dec 31, 2025

This review synthesizes recent large-scale genomic evidence (ROPAD, PD GENEration, MDSGene) to outline the diagnostic yield, ethnic variations, and genotype-phenotype correlations in Parkinson’s disease, emphasizing the transition toward un

Beyond a Positive Result: α-Synuclein Seeding Kinetics Predict Cognitive Decline in Parkinson’s Disease
Neurologybiomarkerscognitive decline

Beyond a Positive Result: α-Synuclein Seeding Kinetics Predict Cognitive Decline in Parkinson’s Disease

By MedXY|Dec 23, 2025

A large-scale longitudinal study reveals that α-synuclein seed amplification assay (SAA) kinetic measures, particularly time to threshold, can differentiate Parkinson’s from PSP and predict future cognitive decline independently of Al

NeurologyAzathioprineclinical trials

Azathioprine in Early Parkinson’s Disease: Trial Fails Primary Endpoint but Reveals Sex-Specific Immune Signals

By MedXY|Dec 19, 2025

The AZA-PD phase 2 trial found that while azathioprine was well-tolerated in early Parkinson’s disease, it did not significantly improve gait-axial scores. However, exploratory data suggests potential motor benefits in female patients

SGLT2 Inhibitors Linked to Lower Parkinson’s Disease Risk Than Metformin in Type 2 Diabetes: Large Real‑World TriNetX Study Signals Class Neuroprotection
Diabetes & EndocrinologymetforminParkinson's disease

SGLT2 Inhibitors Linked to Lower Parkinson’s Disease Risk Than Metformin in Type 2 Diabetes: Large Real‑World TriNetX Study Signals Class Neuroprotection

By MedXY|Nov 1, 2025

A 20‑year TriNetX analysis of 913,428 T2DM patients found SGLT2 inhibitor use associated with a 28% lower Parkinson’s disease risk versus metformin (aHR 0.72), suggesting possible superior neuroprotection and prompting need for prospective

APOE ε4 Allele as an Independent Predictor of Survival in Parkinson’s Disease Patients
NeurologyAPOE ε4Dementia

APOE ε4 Allele as an Independent Predictor of Survival in Parkinson’s Disease Patients

By MedXY|Oct 21, 2025

The APOE ε4 allele significantly reduces survival in Parkinson’s disease patients independently of dementia, linked to mitochondrial dysfunction and ER stress in PD models.

Microbiome Virulence Signatures in the Oral-Gut-Brain Axis: New Insights into Parkinson’s Disease and Cognitive Decline
Clinical Updatescognitive impairmentgut-brain axis

Microbiome Virulence Signatures in the Oral-Gut-Brain Axis: New Insights into Parkinson’s Disease and Cognitive Decline

By MedXY|Oct 6, 2025

This study reveals how virulence factors in oral and gut microbiomes and their translocation affect cognitive impairment in Parkinson’s disease, highlighting novel biomarker potential and the importance of the oral-gut-brain axis for early

Circulating Nanoparticles and Carotenoids as Biomarkers of Rehabilitation Recovery in Parkinson’s Disease
Family Medicine & Nutritionextracellular vesiclesParkinson's disease

Circulating Nanoparticles and Carotenoids as Biomarkers of Rehabilitation Recovery in Parkinson’s Disease

By MedXY|Oct 9, 2025

Intensive treadmill rehabilitation in Parkinson’s disease alters the biochemical composition of circulating extracellular vesicle-like particles, particularly increasing carotenoid content, which correlates with improved gait paramete

Long-Term Safety and Effectiveness of Personalized Adaptive Deep Brain Stimulation in Parkinson’s Disease
Clinical Updatesclinical trialneuromodulation

Long-Term Safety and Effectiveness of Personalized Adaptive Deep Brain Stimulation in Parkinson’s Disease

By MedXY|Oct 9, 2025

This international trial demonstrates that personalized adaptive deep brain stimulation (aDBS) is a safe, effective, and well-tolerated long-term therapy for Parkinson’s disease patients previously stable on continuous DBS.

Metabolic Syndrome Increases Parkinson’s Disease Risk: Implications for Clinical Practice and Prevention
Diabetes & Endocrinologygenetic risklifestyle intervention

Metabolic Syndrome Increases Parkinson’s Disease Risk: Implications for Clinical Practice and Prevention

By MedXY|Oct 5, 2025

A large cohort study reveals that metabolic syndrome significantly raises Parkinson’s disease risk by 39%, with even greater risk in genetically predisposed individuals, highlighting the importance of metabolic health management in PD preve

Unlocking Parkinson’s Prognosis: The Role of α-Synuclein Seed Amplification Kinetics
Clinical Updatescognitive declineParkinson's disease

Unlocking Parkinson’s Prognosis: The Role of α-Synuclein Seed Amplification Kinetics

By MedXY|Oct 3, 2025

A longitudinal study reveals that α-synuclein seed amplification assay kinetic measures enhance diagnostic accuracy and predict cognitive decline in Parkinson’s disease, independent of Alzheimer’s co-pathology.

Medium‑Chain Triglyceride–Supplemented Ketogenic Diet in Parkinson’s Disease: A Small Randomized Feasibility Trial and What It Means for Clinical Practice
Clinical Updatesketogenic dietParkinson's disease

Medium‑Chain Triglyceride–Supplemented Ketogenic Diet in Parkinson’s Disease: A Small Randomized Feasibility Trial and What It Means for Clinical Practice

By MedXY|Oct 2, 2025

A randomized, double‑blind pilot tested an MCT‑supplemented ketogenic diet (MCT‑KD) in 16 people with moderate Parkinson’s disease. The diet was feasible and acceptable, induced nutritional ketosis by day 4, produced metabolic benefits and

AI-Powered Smile Analysis: A Breakthrough in Parkinson’s Disease Screening
AIartificial intelligenceParkinson's disease

AI-Powered Smile Analysis: A Breakthrough in Parkinson’s Disease Screening

By MedXY|Oct 1, 2025

AI analysis of smile videos demonstrates high accuracy in detecting Parkinson’s disease, offering a scalable and accessible screening solution with strong generalizability across populations.

Ask MedXY AI

Most popular

Intimate Health
Five Benefits for Women Continuing Sexual Activity After Menopause
Intimate Health
Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It
Nursing & care
How often should a couple have sex?
Intimate Health
Classic Intimacy Recommendations: How to Help Women Reach Orgasm and Enjoy Mutual Pleasure
Intimate Health
What Makes a Woman "Physiologically Addicted" Is Never Money, But These Two Relationship Qualities